CADM1 and MAL promoter methylation levels in hrHPV‐positive cervical scrapes increase proportional to degree and duration of underlying cervical disease

Combined detection of cell adhesion molecule 1 (CADM1) and T‐lymphocyte maturation‐associated protein (MAL) promoter methylation in cervical scrapes is a promising triage strategy for high‐risk human papillomavirus (hrHPV)‐positive women. Here, CADM1 and MAL DNA methylation levels were analysed in cervical scrapes of hrHPV‐positive women with no underlying high‐grade disease, high‐grade cervical intraepithelial neoplasia (CIN) and cervical cancer. CADM1 and MAL methylation levels in scrapes were first related to CIN‐grade of the corresponding biopsy and second to CIN‐grade stratified by the presence of ‘normal’ or ‘abnormal’ cytology as present in the accompanying scrape preceding the cervical biopsy. The scrapes included 167 women with ≤CIN1, 54 with CIN2/3 and 44 with carcinoma. In a separate series of hrHPV‐positive scrapes of women with CIN2/3 (n = 48), methylation levels were related to duration of preceding hrHPV infection (PHI; <5 and ≥5 years). Methylation levels were determined by quantitative methylation‐specific PCR and normal cytology scrapes of hrHPV‐positive women with histologically ≤CIN1 served as reference. CADM1 and MAL methylation levels increased proportional to severity of the underlying lesion, showing an increase of 5.3‐ and 6.2‐fold in CIN2/3, respectively, and 143.5‐ and 454.9‐fold in carcinomas, respectively, compared to the reference. Methylation levels were also elevated in CIN2/3 with a longer duration of PHI (i.e. 11.5‐ and 13.6‐fold, respectively). Moreover, per histological category, methylation levels were higher in accompanying scrapes with abnormal cytology than in scrapes with normal cytology. Concluding, CADM1 and MAL promoter methylation levels in hrHPV‐positive cervical scrapes are related to the degree and duration of underlying cervical disease and markedly increased in cervical cancer.

[1]  Harald zur Hausen,et al.  Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .

[2]  Jia-xin Yang,et al.  Population-based case–control study on DAPK1, RAR-β2 and MGMT methylation in liquid-based cytology , 2012, Archives of Gynecology and Obstetrics.

[3]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[4]  M. J. van de Vijver,et al.  Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[5]  M. Sherman,et al.  Clinical and Pathological Heterogeneity of Cervical Intraepithelial Neoplasia Grade 3 , 2012, PloS one.

[6]  P. Snijders,et al.  GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes , 2002, Journal of Clinical Microbiology.

[7]  L. Rozendaal,et al.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996 , 2004, Journal of Clinical Pathology.

[8]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[9]  A. Hanselaar.  Criteria for Organized Cervical Screening Programs , 2002, Acta Cytologica.

[10]  J. Lee,et al.  Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens , 2010, Virchows Archiv.

[11]  H. Hollema,et al.  Gene Promoter Methylation Patterns throughout the Process of Cervical Carcinogenesis , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[12]  P. Snijders,et al.  POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women , 2004, International journal of cancer.

[13]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[14]  E. Schuuring,et al.  Methylation Markers for CCNA1 and C13ORF18 Are Strongly Associated with High-Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in Cervical Scrapings , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[15]  H. Hollema,et al.  Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas , 1996, Journal of clinical microbiology.

[16]  H. Lai,et al.  Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. , 2011, American journal of obstetrics and gynecology.

[17]  S. Wacholder,et al.  Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma , 2009, International journal of cancer.

[18]  Johannes Berkhof,et al.  Combined CADM1 and MAL promoter methylation analysis to detect (pre‐)malignant cervical lesions in high‐risk HPV‐positive women , 2011, International journal of cancer.

[19]  Saskia M Wilting,et al.  Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis , 2009, The Journal of pathology.

[20]  C. Meijer,et al.  Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. , 2009, Cancer research.

[21]  Veerle M.H. Coupé,et al.  Combined Promoter Methylation Analysis of CADM1 and MAL: An Objective Triage Tool for High-Risk Human Papillomavirus DNA–Positive Women , 2011, Clinical Cancer Research.

[22]  I. Jacobs,et al.  DNA methylation analysis in liquid‐based cytology for cervical cancer screening , 2009, International journal of cancer.

[23]  C. Meijer,et al.  HPV‐mediated cervical carcinogenesis: concepts and clinical implications , 2006, The Journal of pathology.

[24]  E. Lim,et al.  Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy. , 2010, Gynecologic oncology.

[25]  W. Quint,et al.  Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. , 1989, The American journal of pathology.

[26]  C. Meijer,et al.  Chromosomal profiles of high‐grade cervical intraepithelial neoplasia relate to duration of preceding high‐risk human papillomavirus infection , 2012, International journal of cancer.

[27]  M. Mokni,et al.  Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. , 2011, Pathology, research and practice.

[28]  J. Epstein,et al.  Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. , 2003, The Journal of urology.

[29]  M. Sherman,et al.  Heterogeneity of high‐grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management , 2013, International journal of cancer.

[30]  C. Meijer,et al.  TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. , 2004, Journal of the National Cancer Institute.

[31]  J. Berkhof,et al.  Association between dense CADM1 promoter methylation and reduced protein expression in high‐grade CIN and cervical SCC , 2008, The Journal of pathology.

[32]  M. Sherman,et al.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. , 2009, Gynecologic oncology.

[33]  N. Kiviat,et al.  Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.

[34]  H. Hollema,et al.  A four‐gene methylation marker panel as triage test in high‐risk human papillomavirus positive patients , 2012, International journal of cancer.

[35]  J. Berkhof,et al.  Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening , 2012, International journal of cancer.

[36]  J. Baseman,et al.  The epidemiology of human papillomavirus infections. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.